


Structural Analysis of Bikunin Glycosaminoglycan

Lianli Chi, Jeremy J. Wolff, Tatiana N. Laremore, Odile F. Restaino, Jin Xie, Chiara Schiraldi, Toshihiko Toida, I. Jonathan Amster, and Robert J. Linhardt

J. Am. Chem. Soc., **2008**, 130 (8), 2617-2625 • DOI: 10.1021/ja0778500

Downloaded from <http://pubs.acs.org> on February 8, 2009



More About This Article

Additional resources and features associated with this article are available within the HTML version:

- Supporting Information
- Links to the 1 articles that cite this article, as of the time of this article download
- Access to high resolution figures
- Links to articles and content related to this article
- Copyright permission to reproduce figures and/or text from this article

[View the Full Text HTML](#)

Structural Analysis of Bikunin Glycosaminoglycan

Lianli Chi,[†] Jeremy J. Wolff,[‡] Tatiana N. Laremore,[†] Odile F. Restaino,[§] Jin Xie,[†] Chiara Schiraldi,[§] Toshihiko Toida,^{||} I. Jonathan Amster,[‡] and Robert J. Linhardt^{*,†,||,#}

Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, New York 12180, Department of Chemistry, University of Georgia, Athens, Georgia 30602, Department of Experimental Medicine, Second University of Naples, Naples 80137, Italy, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 263-8522, Japan, Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, Department of Biology, Rensselaer Polytechnic Institute, Troy, New York 12180

Received October 12, 2007; E-mail: linhar@rpi.edu

Abstract: The structure of an intact glycosaminoglycan (GAG) chain of the bikunin proteoglycan (PG) was analyzed using a combined top-down and bottom-up sequencing strategy. PGs are proteins with one or more linear, high-molecular weight, sulfated GAG polysaccharides O-linked to serine or threonine residues. GAGs are often responsible for the biological functions of PGs, and subtle variations in the GAG structure have pronounced physiological effects. Bikunin is a serine protease inhibitor found in human amniotic fluid, plasma, and urine. Bikunin is posttranslationally modified with a chondroitin sulfate (CS) chain, O-linked to a serine residue of the core protein. Recent studies have shown that the CS chain of bikunin plays an important role in the physiological and pathological functions of this PG. While no PG or GAG has yet been sequenced, bikunin, the least complex PG, offers a compelling target. Electrospray ionization Fourier transform-ion cyclotron resonance mass spectrometry (ESI FTICR-MS) permitted the identification of several major components in the GAG mixture having molecular masses in a range of 5505–7102 Da. This is the first report of a mass spectrum of an intact GAG component of a PG. FTICR-MS analysis of a size-uniform fraction of bikunin GAG mixture obtained by preparative polyacrylamide gel electrophoresis, allowed the determination of chain length and number of sulfo groups in the intact GAGs.

Introduction

Many physiological and pathological processes such as fertilization, embryonic development, immune response, inflammation, angiogenesis, tumorigenesis, and metastasis are mediated by proteoglycans (PGs).^{1–6} PGs comprise a protein core and one or more glycosaminoglycan (GAG) chains. GAG components of PGs are linear, sulfated polysaccharides containing hexosamine and uronic acid (or hexose) disaccharide repeating sequence and include keratan sulfate (KS), heparin (HP), heparan sulfate (HS), chondroitin sulfate (CS), and dermatan sulfate (DS).⁷ PGs are ubiquitously present in the extracellular matrix (ECM) and on cell surfaces in animal tissues where they serve as structural elements and participate in a

number of regulatory and signaling events.⁷ High specificity of interactions between PGs and other components of ECM and/or cell surface receptors is defined by the backbone structure and modification pattern of the GAG chain.^{1,4,7} Biosynthesis of GAGs is a nontemplate-driven process and takes place in the Golgi compartment of eukaryotic cells in response to an external stimulus or at a particular stage of development.⁸

While the importance of PGs and their potential as new therapeutic agents, targets, and disease markers are well recognized,^{3,9–12} sequence determination of GAGs remains a challenging task. Methods for GAG sequencing reported to date rely on a bottom-up approach which involves characterization of depolymerized fragments of GAGs that can be assembled like pieces of a puzzle into motifs or domains.^{13,14} The aim of the present work was to combine a new top-down approach that takes advantage of state-of-the-art mass spectrometric techniques with bottom-up approaches in one sequencing strategy and apply it in the characterization of a PG.

[†] Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute.

[‡] University of Georgia.

[§] Second University of Naples.

^{||} Chiba University.

[†] Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute.

[#] Department of Biology, Rensselaer Polytechnic Institute.

- (1) Bulow, H. E.; Hobert, O. *Annu. Rev. Cell Dev. Biol.* **2006**, *22*, 375–407.
- (2) Handel, T. M.; Johnson, Z.; Crown, S. E.; Lau, E. K.; Sweeney, M.; Proudfoot, A. E. *Annu. Rev. Biochem.* **2005**, *74*, 385–410.
- (3) Iozzo, R. V. *Nat. Rev. Mol. Cell Biol.* **2005**, *6*, 646–656.
- (4) Lamanna, W. C.; Kalus, I.; Padva, M.; Baldwin, R. J.; Merry, C. L. R.; Dierks, T. *J. Biotechnol.* **2007**, *129*, 290–307.
- (5) Lin, X. *Development* **2004**, *131*, 6009–6021.
- (6) Timar, J.; Lapis, K.; Dudas, J.; Sebestyen, A.; Kopper, L.; Kovalszky, I. *Semin. Cancer Biol.* **2002**, *12*, 173–186.
- (7) Capila, I.; Linhardt, R. J. *Angew. Chem., Int. Ed.* **2002**, *41*, 390–412.

- (8) Sasisekharan, R.; Venkataraman, G. *Curr. Opin. Chem. Biol.* **2000**, *4*, 626–631.
- (9) Gesslbauer, B.; Kungl, A. J. *Curr. Opin. Mol. Ther.* **2006**, *8*, 521–528.
- (10) Powell, A. K.; Yates, E. A.; Fernig, D. G.; Turnbull, J. E. *Glycobiology* **2004**, *14*, 17R–30R.
- (11) Proudfoot, A. E. I. *Biochem. Soc. Trans.* **2006**, *34*, 422–426.
- (12) Raman, R.; Sasisekharan, R. *Chem. Biol.* **2005**, *12*, 267–277.
- (13) Merry, C. L. R.; Lyon, M.; Deakin, J. A.; Hopwood, J. J.; Gallagher, J. T. *J. Biol. Chem.* **1999**, *274*, 18455–18462.
- (14) Venkataraman, G.; Shriver, Z.; Raman, R.; Sasisekharan, R. *Science* **1999**, *286*, 537–542.

Bikunin, used in the present study, is a small PG, a member of the Kunitz-type, or kunitin family of serine protease inhibitors.^{15–17} Bikunin is encoded by an α -microglobulin-bikunin precursor gene, AMBP (Swiss-Prot entry AMBP_HUMAN, P02760). The precursor protein is proteolyzed releasing α -1-microglobulin and bikunin, two proteins with apparently unrelated functions.^{15–18} Before secretion, bikunin is posttranslationally modified in the Golgi with both an *N*-glycan and a CS GAG chain.^{19–21} The CS GAG chain of bikunin is *O*-linked to the Ser₁₀ of the core polypeptide (Ser₂₁₅ in AMBP) through a xylopyranose (Xyl) residue and belongs to the chondroitin 4-sulfate (CS-A) family.^{19,22} The linkage region hexasaccharide of the bikunin GAG chain has been characterized by Sugahara and co-workers through a combination of radiolabeling, enzymatic depolymerization, high performance liquid chromatography (HPLC), and fast-atom bombardment mass spectrometry.²³ The linkage region hexasaccharide, derived from pooled human plasma bikunin, reportedly was the only linkage region-derived structure present in the sample and had a sequence $\Delta\text{UA}(1\rightarrow3)\text{-}\beta\text{-D-GalNAc4S}(1\rightarrow4)\text{-}\beta\text{-D-GlcA}(1\rightarrow3)\text{-}\beta\text{-D-Gal4S}(1\rightarrow4)\text{-}\beta\text{-D-Gal}(1\rightarrow4)\text{-D-Xylol}$ (where $\Delta\text{UA} = 4\text{-deoxy-}\alpha\text{-L-threo-hex-4-enopyranosyluronic acid}$; GlcA = glucopyranosyluronic acid; Gal = galactopyranose; and S = sulfate).²³ These workers reported that the linkage region hexasaccharide in urinary bikunin is also homogeneous and has the same structure as that in plasma bikunin.²³ These results conflict with an earlier report by Toyoda et al.²⁴ in which an unsulfated linkage region tetrasaccharide was found in the CS-A chain of urinary bikunin. Enghild and co-workers examined human plasma bikunin obtained from multiple volunteers.^{22,25} Based on the results of gradient polyacrylamide gel electrophoresis (PAGE) analysis of fluorophor-labeled linkage region oligosaccharides, this study suggested that both monosulfated and unsulfated linkage region hexasaccharides were present in plasma bikunin.²² Reports also vary in their determination of the average chain length of bikunin GAG and the number and location of sulfo groups,^{15,16,22,24,26,27} which can be explained by the fact that many studies examined pooled samples from different biological fluids. Bikunin GAG has been reported to contain 12–18 GlcAGalNAc disaccharides^{22,26} and 5 sulfo groups all clustered at the reducing end.^{15,22,24,26}

During the past decade, the interest in structural analysis of bikunin GAG has increasingly shifted from purely academic to

diagnostic and therapeutic.^{15,16,28–33} The bikunin GAG structure has been demonstrated to vary, depending on the physiological or pathophysiological conditions. A disaccharide composition analysis of the urinary bikunin GAGs obtained from a septic shock patient showed a significantly lower ratio of sulfated to unsulfated disaccharides: 1:6.2 as opposed to 1:1.8 in normal plasma.²⁶ The GAG chain length was increased in the bikunin sample from the septic shock patient, compared to that in the normal bikunin sample.²⁶ Bikunin GAG is important in solubilizing urinary calcium oxalate.³⁴ Urinary bikunin concentration has been found to decrease in patients with renal stones.^{34–38} Bikunin PG inhibits a number of proteases including matrix proteases involved in cancer metastasis.³¹ The addition of bikunin treatment to standard chemotherapy improves the survival of patients with surgically treated advanced epithelial ovarian cancer.³¹

While the protein component of bikunin is well characterized,^{30,39} its GAG structure has received less attention, due to the technical difficulty associated with GAG analysis. In a few publications describing structural analysis of bikunin GAG, both the chain length and sulfation degree were determined indirectly. The chain length was calculated from matrix-assisted laser desorption ionization (MALDI) mass spectra as a difference in mass between intact bikunin PG and enzymatically or chemically deglycosylated protein core.^{22,26} The number of sulfo groups in the GAG chain was calculated from disaccharide composition as a ratio of unsulfated disaccharides to sulfated disaccharides and varies from 1.8:1²⁶ to 3:1.²² Since in both cases the source of bikunin GAG was human plasma, the variability could be attributed to different quantification methods. Nonetheless, the absolute number of sulfo groups in bikunin GAG is impossible to determine from the disaccharide ratio unless the chain length is known.

The present work describes the first direct mass spectral analysis of an intact GAG chain both as a mixture and after a separation step. The high resolving power of Fourier transform ion cyclotron resonance (FTICR)-MS analysis is applied to the determination of the number of disaccharides and sulfo groups in individual bikunin GAG chains.

Experimental Section

Materials. Bikunin (lot C170) was from Mochida Pharmaceuticals (Tokyo, Japan). Actinase E was from Kaken Biochemicals (Tokyo, Japan). Chondroitinase ABC (EC 4.2.2.4 from *Proteus vulgaris*),

- (15) Fries, E.; Blom, A. M. *Int. J. Biochem. Cell Biol.* **2000**, *32*, 125–137.
- (16) Fries, E.; Kaczmarczyk, A. *Acta Biochim. Pol.* **2003**, *50*, 735–742.
- (17) Zhuo, L.; Salustri, A.; Kimata, K. *Glycoconjugate J.* **2003**, *19*, 241–247.
- (18) Diarra-Mehrpour, M.; Bourguignon, J.; Sesboue, R.; Salier, J. P.; Leveillard, T.; Martin, J. P. *Eur. J. Biochem.* **1990**, *191*, 131–139.
- (19) Enghild, J. J.; Salvesen, G.; Hefta, S. A.; Thogersen, I. B.; Rutherford, S.; Pizzo, S. V. *J. Biol. Chem.* **1991**, *266*, 747–751.
- (20) Morelle, W.; Capon, C.; Balduyck, M.; Sautiere, P.; Kouach, M.; Michalski, C.; Fournet, B.; Mizon, J. *Eur. J. Biochem.* **1994**, *221*, 881–888.
- (21) Zhuo, L.; Hascall, V. C.; Kimata, K. *J. Biol. Chem.* **2004**, *279*, 38079–38082.
- (22) Enghild, J. J.; Thogersen, I. B.; Cheng, F.; Fransson, L. A.; Roepstorff, P.; Rahbek-Nielsen, H. *Biochemistry* **1999**, *38*, 11804–11813.
- (23) Yamada, S.; Oyama, M.; Kinugasa, H.; Nakagawa, T.; Kawasaki, T.; Nagasawa, S.; Khoo, K.-H.; Morris, H. R.; Dell, A.; Sugahara, K. **1995**, *5*, 335–341.
- (24) Toyoda, H.; Kobayashi, S.; Sakamoto, S.; Toida, T.; Imanari, T. *Biol. Pharm. Bull.* **1993**, *16*, 945–947.
- (25) Enghild, J. J.; Thogersen, I. B.; Pizzo, S. V.; Salvesen, G. *J. Biol. Chem.* **1989**, *264*, 15975–15981.
- (26) Capon, C.; Mizon, C.; Lemoine, J.; Rodie-Talbere, P.; Mizon, J. *Biochimie* **2003**, *85*, 101–107.
- (27) Mizon, C.; Mairie, C.; Balduyck, M.; Hachulla, E.; Mizon, J. *Eur. J. Biochem.* **2001**, *268*, 2717.

- (28) Bergsland, K. J.; Kelly, J. K.; Coe, B. J.; Coe, F. L. *Am. J. Physiol. Renal Physiol.* **2006**, *291*, F530–F536.
- (29) Jessen, T. E.; Odum, L. *Reproduction* **2003**, *125*, 27–31.
- (30) Josic, D.; Brown, M. K.; Huang, F.; Lim, Y. P.; Rucevic, M.; Clifton, J. G.; Hixson, D. C. *Proteomics* **2006**, *6*, 2874–2885.
- (31) Kobayashi, H.; Suzuki, M.; Hirashima, Y.; Terao, T. *Biol. Chem.* **2003**, *384*, 749–754.
- (32) Kobayashi, H.; Yagyu, T.; Inagaki, K.; Kondo, T.; Suzuki, M.; Kanayama, N.; Terao, T. *Int. J. Cancer* **2004**, *110*, 134–139.
- (33) Kobayashi, H.; Yagyu, T.; Inagaki, K.; Kondo, T.; Suzuki, M.; Kanayama, N.; Terao, T. *Cancer* **2004**, *100*, 869–877.
- (34) Suzuki, M.; Kobayashi, H.; Kageyama, S.; Shibata, K.; Fujie, M.; Terao, T. *J. Urol.* **2001**, *166*, 268–274.
- (35) Iida, S.; Peck, A. B.; Johnson-Tardieu, J.; Moriyama, M.; Glenton, P. A.; Byer, K. J.; Khan, S. R. *J. Am. Soc. Nephrol.* **1999**, *10*, 986–996.
- (36) Medetognon-Benissan, J.; Tardivel, S.; Hennequin, C.; Daudon, M.; Druce, T.; Lacour, B. *Urol. Res.* **1999**, *27*, 69–75.
- (37) Tardivel, S.; Médetognon, J.; Randoux, C.; Kébedé, M.; Driéke, T.; Daudon, M.; Hennequin, C.; Lacour, B. *Urol. Res.* **1999**, *27*, 243–249.
- (38) Verkoelen, C. F. *J. Am. Soc. Nephrol.* **2006**, *17*, 1673–1687.
- (39) Delaria, K. A.; Muller, D. K.; Marlor, C. W.; Brown, J. E.; Das, R. C.; Rocznik, S. O.; Tamburini, P. P. *J. Biol. Chem.* **1997**, *272*, 12209–12214.

chondroitin AC endolyase (EC 4.2.2.5 from *Flavobacterium heparinum*), chondro-4-sulfatase, chondro-6-sulfatase (EC 3.1.6.9 and 3.1.6.10, from *P. vulgaris*) were from Seikagaku (East Falmouth, MA). Chondroitinase B (from *F. heparinum*) and chondroitin AC exolyase (EC 4.2.2.5, from *Arthrobacter aurescens*) were from Sigma (St. Louis, MO). Materials, equipment, and reagents for PAGE were from Bio-Rad (Hercules, CA). All other chemicals were from Fisher; all solvents were HPLC grade.

Bikunin Proteoglycan. Bikunin PG was purified from excipients and buffer salts in drug formulation by dialysis against distilled water using 3500 molecular weight cutoff (MWCO) membranes. The purified PG was freeze-dried and stored at $-20\text{ }^{\circ}\text{C}$.

Bikunin Peptidoglycan. Bikunin peptidoglycan (pG) was prepared by the treatment of purified bikunin PG with actinase, a nonspecific protease. A 1% solution of actinase in 50 mM Tris-acetate buffer, pH 8, was added to a 6 mg/mL aqueous solution of bikunin PG in a volumetric ratio of 1:5. After an overnight incubation at $45\text{ }^{\circ}\text{C}$, sufficient amounts of urea and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) were added to the digestion mixture to obtain 8 M and 2% concentrations respectively.⁴⁰ A strong anion-exchange (SAX) spin-column (Vivapure Q, VivaScience, Hannover, Germany) was equilibrated with 8 M urea, 2% CHAPS, pH 8.5, and the digestion mixture containing 8 M urea and 2% CHAPS was loaded on the SAX membrane by centrifugation at 500g for 15 min. The sample bound to the membrane was washed once with the urea/CHAPS solution and 5 times with 0.1 M NaCl, after which bikunin pG was eluted with three 1-mL portions of 16% aqueous NaCl. Peptidoglycan was desalted by precipitation from 80% methanol at $4\text{ }^{\circ}\text{C}$ overnight, followed by centrifugation. The precipitate was dissolved in water, freeze-dried, and stored at $-20\text{ }^{\circ}\text{C}$.

Bikunin GAG Mixture. GAG component of bikunin pG was released by β -elimination under reducing conditions. Bikunin pG was dissolved in a 0.4 M NaOH solution containing 0.3 M NaBH_4 at ~ 10 mg/mL concentration of pG. The reaction was allowed to proceed for 24 h at $4\text{ }^{\circ}\text{C}$, after which it was carefully neutralized with 1 M HCl. The resulting bikunin GAG mixture was separated from low-molecular-weight contaminants by centrifugal filtration using a 3000 MWCO membrane (Microcon YM-3, Millipore, Billerica, MA).

Isolation and Analysis of Size-Similar GAG Fractions. Bikunin GAG chains were first separated using isocratic polyacrylamide gel electrophoresis (PAGE). The resolving gel contained 15% total acrylamide, and the stacking gel contained 5% total acrylamide.⁴¹ Bikunin GAG mixture (3–5 mg/mL) was loaded on a 20 cm \times 20 cm gel and run in a Protean II electrophoresis system (Bio-Rad, Hercules, CA) for 30 min at 200 V, followed by 6 h at 400 V. The separated GAG chains were immediately transferred from the polyacrylamide gel to a positively charged nylon membrane (Zeta-Probe, Bio-Rad) using a vertical blotting apparatus (Criterion Blotter, Bio-Rad).⁴¹ Electrotransfer was carried out at 25 V for 12 min in a 50 mM Tris, 60 mM glycine, 20% methanol blotting buffer, after which the membrane was soaked in water for 10 min followed by 8 M urea, 2% CHAPS for 30 min and water again. A vertical strip was cut from the center of the nylon membrane, stained with Alcian blue, and used as a reference for locating the GAG bands on the unstained parts of the membrane. The membrane was cut into strips containing separated GAGs, and the GAGs were released by soaking the strips in 2 M NaCl solution. Separated GAG chains were desalted using the 3000 MWCO centrifugal filtration membranes (Microcon YM-3, Millipore).

NMR Spectroscopy. ^{31}P NMR spectra were recorded on a 300 MHz Varian instrument using sodium dibasic phosphate as external reference. ^1H NMR spectra were recorded on a 500 MHz JEOL GSX500 α instrument. After lyophilization from 99.9% $^2\text{H}_2\text{O}$, bikunin GAG sample (13 mM based on a molecular mass of 6 kDa) was dissolved in 99.9%




Figure 1. (A) Positive-ion, linear MALDI-TOF mass spectrum of bikunin PG. Calibrant peaks are labeled Lys (chicken egg lysozyme) and Ins (bovine insulin). (B) Negative-ion, linear MALDI-TOF mass spectrum of bikunin peptidoglycan. Unassigned peak is marked with an asterisk.

$^2\text{H}_2\text{O}$ for analysis and transferred to a Shigemi NMR microtube. Presaturation of the residual HO^2H peak was achieved during the relaxation delay. The spectra were recorded at room temperature and at 333 K, with a flip angle of 90° , spectral width of 2806 Hz, and a minimum of 64 accumulation pulses. Line broadening of 1 Hz was applied in the data processing.

Enzymatic Analysis. Two $60\text{-}\mu\text{L}$ aliquots of 1 mg/mL bikunin GAG mixture were treated with 0.2 U chondroitinase B and 0.2 U chondroitinase AC overnight at $37\text{ }^{\circ}\text{C}$. Products were analyzed by PAGE using Alcian blue and silver staining.⁴²

Two aliquots of the chondroitinase AC digestion products were treated with 0.1 U of chondro-4-sulfatase and 0.1 U of chondro-6-sulfatase overnight at $37\text{ }^{\circ}\text{C}$. Resulting mixtures were analyzed by reverse-phase high-performance liquid chromatography (RP HPLC) with postcolumn fluorescence detection.

Disaccharide Analysis. Bikunin GAG mixture (50–100 μg) was treated with a mixture of 0.1 U chondroitinase AC II and 0.2 U chondroitinase ABC overnight at $37\text{ }^{\circ}\text{C}$ and analyzed by RP HPLC with postcolumn fluorescence detection. The digestion mixture was separated on a 5 μm , 4.6 mm \times 250 mm Supelco Discovery C18 column (Sigma) using a linear gradient of 0–100% B over 35 min and a flow rate of 1.0 mL/min. Mobile phase A contained 8% acetonitrile and 3 mM tetrabutylamine, pH 5 adjusted with HCl. Mobile phase B contained 8% acetonitrile, 3 mM tetrabutylamine, and 200 mM NaCl, pH 5 adjusted with HCl. Column temperature was kept at $55\text{ }^{\circ}\text{C}$. Fluorescent derivatization was achieved by introducing mobile phases C containing 1% 2-cyanoacetamide and D containing 750 mM NaOH into the postcolumn flow at a rate of 0.2 mL/min. Derivatization

(40) Zhang, F.; Sun, P.; Munoz, E.; Chi, L.; Sakai, S.; Toida, T.; Zhang, H.; Mousa, S.; Linhardt, R. J. *Anal. Biochem.* **2006**, *353*, 284–286.

(41) Al-Hakim, A.; Linhardt, R. J. *Electrophoresis* **1990**, *11*, 23–28.

(42) Al-Hakim, A.; Linhardt, R. J. *Appl. Theor. Electrophor.* **1991**, *1*, 305.




Figure 2. Outline of the analytical strategy, showing amounts of sample in micrograms used in each experimental step.

was carried out at 120 °C, and the products were detected using λ_{ex} 346 nm and λ_{em} 410 nm.

Mass Spectrometry. UV-MALDI-TOF mass spectra of bikunin PG and pG were acquired on a ToFSpec E mass spectrometer (Micromass) in linear mode with positive ion detection. Spectra were internally calibrated with bovine insulin, hen egg lysozyme, and cytochrome C. Sinapinic acid was used for the analysis of bikunin PG, and bis-1,1,3,3-tetramethylguanidinium α -cyano-4-hydroxycinnamate (G_2CHCA) was used for the analysis of bikunin pG.⁴³

The negative-ion ESI-FTICR mass spectra of bikunin GAG mixture were acquired on a 7T Bruker Apex IV QeFTMS instrument fitted with an Apollo II electrospray ion source. Bikunin GAG sample was dissolved in 50% aqueous methanol to a concentration of 0.1 mg/mL and directly infused using nanospray through a pulled fused silica tip (model FS360-75-15-D-5, New Objective, Woburn, MA) at a flow rate of 10 $\mu\text{L}/\text{h}$.

For electron-detachment dissociation (EDD)⁴⁴ MS analysis of the nonreducing end (NRE) monosulfated trisaccharide, precursor ions were isolated in the external quadrupole and accumulated for 1–2 s before the injection into the FTMS cell. The isolation/cell fill cycle was repeated up to six times. The selection of the precursor ion was further refined by using in-cell isolation with a coherent harmonic excitation frequency (CHEF)⁴⁵ event. The precursor ions were then irradiated with

electrons for 1 s. For electron irradiation, the cathode bias was set to -19 V, the ECD lens was set to -17.5 V \pm 0.5 V, and the cathode heater was set to 1.6 A. Each mass spectrum was a result of averaging 24 acquisitions. For each mass spectrum, 512 k points were acquired, padded with one zero fill, and apodized using a sinebell window. Background spectra were acquired by leaving all parameters the same but setting the cathode bias to 0 V to ensure that no electrons reached the analyzer cell.

ESI-LC-MS and tandem MS analyses of oligosaccharides derived from bikunin GAG were performed on an Agilent 1100 LC-MSD instrument equipped with an ion trap mass analyzer and an Agilent 1100 series HPLC system. The oligosaccharides were separated on a Zorbax SB C-18 capillary column (5 μm , 0.5 mm \times 250 mm, Agilent, Palo Alto, CA). A binary mobile phase was delivered at a flow rate of 10 $\mu\text{L}/\text{min}$, and the sample was introduced through a micro-spray nebulizer. Mobile phase A contained 15 mM tributylamine (in place of the nonvolatile tetrabutylammonium chloride used in RP HPLC), 50 mM ammonium acetate, and 15% acetonitrile. Mobile phase B contained 15 mM tributylamine, 50 mM ammonium acetate, and 65% acetonitrile. The separation was achieved using the following gradient: 0% B 20 min, 0–50% B 20–40 min, 50–70% B 40–60 min. All mass spectra were acquired in the negative ionization mode.

Results and Discussion

Bikunin Proteoglycan and Peptidoglycan. Bikunin drug formulation contained 46% PG and 54% excipients and buffer salts that were removed by dialysis. Recovered bikunin PG was analyzed by MALDI-TOF-MS in the linear positive-ion mode

(43) Laremore, T. N.; Zhang, F.; Linhardt, R. J. *Anal. Chem.* **2007**, *79*, 1604–1610.

(44) Wolff, J. J.; Amster, I. J.; Chi, L.; Linhardt, R. J. *J. Am. Soc. Mass Spectrom.* **2007**, *18*, 234–244.

(45) Heck, A. J. R.; de Koning, L. J.; Pinkse, F. A.; Nibbering, N. M. M. *Rapid Commun. Mass Spectrom.* **1991**, *5*, 406–414.

using sinapinic acid and G₂CHCA as matrices. MALDI mass spectra of bikunin PG contained a peak at 24,100 *m/z*, attributed to the bikunin PG, and a peak at 18,700 *m/z*, corresponding to a bikunin PG with a truncated or missing GAG chain (Figure 1A). These results are consistent with previous MALDI-MS analyses of bikunin PG.^{22,26} Proteolysis of bikunin PG, followed by SAX purification,⁴⁰ afforded bikunin peptidoglycan (pG) in a 21% yield. Purified pG was analyzed by MALDI-TOF-MS in the linear mode with negative-ion detection. A MALDI mass spectrum acquired using G₂CHCA as a matrix showed a broad peak at ~6,000 *m/z* (Figure 1B). The shape of the pG peak reflected a high degree of polydispersity in the sample. The use of sinapinic acid and 2,5-dihydroxybenzoic acid matrices did not result in a pG signal.

Bikunin GAG Mixture. Bikunin GAG mixture, obtained by reductive β -elimination, was characterized by PAGE, ¹H and ³¹P NMR, enzymatic studies, and ESI-FTICR-MS (Figure 2). Using heparin oligosaccharide standards, the average molecular mass of the bikunin GAG chains was estimated ~6 kDa by PAGE analysis.⁴⁶

¹H NMR analysis of the GAG mixture was performed at 60 °C to avoid overlapping of the H-4 proton peak of 4-*O*-sulfo-GalNAc and the HO²H peak observed at room temperature. At 60 °C, the upfield shift of the HO²H peak permitted the H-4 signal of 4-*O*-sulfo-GalNAc residue to be observed at 4.8 ppm. The ¹H NMR spectrum of bikunin GAG was consistent with a chondroitin 4-sulfate (CS-A) structure containing both $\rightarrow 3$ - β -D-GalNAc(1 \rightarrow 4)- β -D-GlcA(1 \rightarrow and $\rightarrow 3$ - β -D-GalNAc4S-(1 \rightarrow 4)- β -D-GlcA(1 \rightarrow disaccharide repeating sequences.⁴⁷

A linkage hexasaccharide in shark cartilage chondroitin 6-sulfate (CS-C) has been reported to contain a 2-*O*-phosphoryl residue.⁴⁸ To examine the possibility that bikunin GAG might also be phosphorylated, ³¹P NMR analysis was performed on the bikunin GAG mixture using sodium dibasic phosphate as an internal reference. No peak corresponding to a phospho group was observed, with detection sensitivity of 1.25 mM HPO₄²⁻, indicating that there was less than one phospho group substituent per ten bikunin GAG chains.

The C-5 epimerization of uronic acid residues in bikunin GAG was determined by exhaustive digestion of the GAG mixture with chondroitinase ABC, endolytic chondroitinase AC, and chondroitinase B. Chondroitinase ABC converts CS-A, CS-C, and dermatan sulfate (CS-B) completely to disaccharide products.^{49,50} Endolytic chondroitinase AC acts exclusively on the β -1,4-galactosaminidic bonds between GalNAc and GlcA.⁵¹ In contrast, chondroitinase B only cleaves β -1,4-galactosaminidic bonds between 4-*O*-sulfo-GalNAc and IdoA residues, acting exclusively on CS-B.^{50,51} The sequential use of these chondroitinases followed by PAGE analysis confirmed that the bikunin was a CS GAG, containing no IdoA residues. The disaccharide products of exhaustive depolymerization of bikunin GAG with chondroitinase ABC and endolytic chondroitinase AC were analyzed by RP-IP-HPLC using postcolumn fluores-




Figure 3. Improvement in S/N in the FTICR mass spectrum of the bikunin CS mixture (a) achieved by acquiring MS data over narrow *m/z* regions using quadrupole mass filter (b). Combining mass spectra acquired over narrow overlapping *m/z* regions afforded a full spectrum shown in panel (c).

cence detection. The resulting chromatogram contained two peaks with retention times corresponding to those of the unsulfated disaccharide standard Δ UA(1 \rightarrow 3)-D-GalNAc and monosulfated disaccharide standard Δ UA(1 \rightarrow 3)-D-GalNAc4S. Based on the areas under the chromatographic peaks bikunin GAG mixture contained Δ UA(1 \rightarrow 3)-D-GalNAc and Δ UA(1 \rightarrow 3)-D-GalNAc4S in a ratio of 1.7:1. This ratio is consistent with the bikunin GAG disaccharide composition reported by Capon and co-workers.²⁶

Since the retention times for Δ UA(1 \rightarrow 3)-D-GalNAc4S and Δ UA(1 \rightarrow 3)-D-GalNAc6S are close, it was important to eliminate the possibility that a small amount of Δ UA(1 \rightarrow 3)-D-GalNAc6S was present. The disaccharide mixture was treated with 4-*O*-sulfatase, an enzyme that selectively desulfates 4-*O*-sulfo-GalNAc, and with 6-*O*-sulfatase, which selectively des-

- (46) Edens, R. E.; Al-Hakim, A.; Weiler, J. M.; Rethwisch, D. G.; Fareed, J.; Linhardt, R. J. *J. Pharm. Sci.* **1992**, *81*, 823–827.
 (47) Toida, T.; Toyoda, H.; Imanari, T. *Anal. Sci.* **1993**, *9*, 53–58.
 (48) Sugahara, K.; Ohi, Y.; Harada, T.; de Waard, P.; Vliegthart, J. F. *J. Biol. Chem.* **1992**, *267*, 6027–6035.
 (49) Hamai, A.; Hashimoto, N.; Mochizuki, H.; Kato, F.; Makiguchi, Y.; Horie, K.; Suzuki, S. *J. Biol. Chem.* **1997**, *272*, 9123–9130.
 (50) Jandik, K.; Gu, K.; Linhardt, R. J. *Glycobiology* **1994**, *4*, 289–296.
 (51) Gu, K.; Liu, J.; Pervin, A.; Linhardt, R. J. *Carbohydr. Res.* **1993**, *244*, 369–377.

Table 1. Neutral Masses Obtained in the FTICR-MS Analysis of Bikunin GAG

I	II	III	IV	V	VI	VII	VIII	IX
5571		6074		6453			7131	7190
5594	5972	6096		6475	6752	6876	7153	7212
5615	5994	6118	6351	6497	6774	6898	7175	7234
5637	6016	6142	6372	6519	6796	6920	7198	7256
5659	6038	6164	6417	6541	6818	6942	7220	7278
5681	6060	6184	6439	6563	6840	6964	7242	7300
				6585	6862	6986	7264	7322

ulfates 6-*O*-sulfo-GalNAc.⁵² Analysis of the enzymatic reaction mixture by RP-IP-HPLC with postcolumn fluorescence detection indicated that the GAG component of bikunin does not contain 6-*O*-sulfo-GalNAc.

The molecular weight determination of intact bikunin GAGs was performed using ESI-FTICR-MS. Initial MS analysis afforded a very complex mass spectrum containing peaks corresponding to the multiple charge states and Na/H heterogeneity products of each polysaccharide chain in the mixture (Figure 3A). The signal-to-noise ratio (S/N) observed in the initial FTICR-MS experiment was inadequate for a confident peak assignment due to the sample polydispersity. An improvement in the quality of mass spectral information was achieved by isolating ions within a narrow *m/z* range using a quadrupole mass filter (Figure 3B). Combining a series of mass spectra acquired over narrow, overlapping *m/z* regions, a full mass spectrum of the bikunin GAG mixture was afforded with greatly enhanced S/N (Figure 3C). Mass deconvolution of the several

hundreds of *m/z* values observed in the full spectrum yielded 54 major neutral masses that were arranged into nine groups (Table 1). Each group of masses corresponds to a unique saccharide composition with a mass *M* in which *n* protons are replaced by *n* sodium cations, resulting in a mass difference of 22 mass units between successive members of a group. The Na/H exchange is commonly observed in mass spectra of acidic compounds.^{53,54} ESI-FTICR-MS data interpretation was based on information obtained from the PAGE, ¹H and ³¹P NMR, and enzymatic experiments.

First, both PAGE and FTICR-MS analyses place the molecular mass of bikunin GAGs in the 5–7 kDa range, which corresponds to the chain lengths of 12–17 disaccharides. Second, each CS-A GAG chain must contain a linkage region tetrasaccharide β-D-GlcA(1→3)-β-D-Gal(1→4)-β-D-Gal(1→4)-D-Xylol with a residue mass of 634 amu.^{23,55} The chain could be terminated with either a GlcA residue and consist of an even number of monosaccharides, or a GalNAc residue and consist of an odd number of monosaccharides. Finally, a GAG chain could be modified by sulfation on one or more GalNAc residues and/or a Gal residue of the linkage tetrasaccharide. Thus, the mass of a bikunin GAG chain can be calculated using expression 1 or 2, where *M*_{odd} is the mass of GalNAc-terminated GAG chain; *M*_{even} is the mass of GlcA-terminated GAG chain. Each chain contains the linkage tetrasaccharide (634 amu), *di* number of disaccharides (Δ379 amu), *s* number of SO₃ groups (Δ80 amu), and *n* number of Na⁺ replacing the H⁺ (Δ22 amu). A total of 18 amu is added to the chain termini to account for H

Table 2. Example of Master List of Possible Neutral Masses Generated on the Basis of the Results of the Oligosaccharide (Bottom-Up) Analysis^a

<i>di</i> = 14, GalNAc-terminated						<i>di</i> = 14, GlcA-terminated						<i>di</i> = 15, GalNAc-terminated						<i>di</i> = 15, GlcA-terminated						
<i>n</i>	<i>s</i> = 4	<i>s</i> = 5	<i>s</i> = 6	<i>s</i> = 7	<i>s</i> = 8	<i>n</i>	<i>s</i> = 4	<i>s</i> = 5	<i>s</i> = 6	<i>s</i> = 7	<i>s</i> = 8	<i>n</i>	<i>s</i> = 4	<i>s</i> = 5	<i>s</i> = 6	<i>s</i> = 7	<i>s</i> = 8	<i>n</i>	<i>s</i> = 4	<i>s</i> = 5	<i>s</i> = 6	<i>s</i> = 7	<i>s</i> = 8	
0	6483	6563	6643	6723	6803	0	6280	6360	6440	6520	6600	0	6862	6942	7022	7102	7182	0	6659	6739	6819	6899	6979	
1	6505	6585	6665	6745	6825	1	6302	6382	6462	6542	6622	1	6884	6964	7044	7124	7204	1	6681	6761	6841	6921	7001	
2	6527	6607	6687	6767	6847	2	6324	6404	6484	6564	6644	2	6906	6986	7066	7146	7226	2	6703	6783	6863	6943	7023	
3	6549	6629	6709	6789	6869	3	6346	6426	6506	6586	6666	3	6928	7008	7088	7168	7248	3	6725	6805	6885	6965	7045	
4	6571	6651	6731	6811	6891	4	6368	6448	6528	6608	6688	4	6950	7030	7110	7190	7270	4	6747	6827	6907	6987	7067	
5	6593	6673	6753	6833	6913	5	6390	6470	6550	6630	6710	5	6972	7052	7132	7212	7292	5	6769	6849	6929	7009	7089	
6	6615	6695	6775	6855	6935	6	6412	6492	6572	6652	6732	6	6994	7074	7154	7234	7314	6	6791	6871	6951	7031	7111	
7	6637	6717	6797	6877	6957	7	6434	6514	6594	6674	6754	7	7016	7096	7176	7256	7336	7	6813	6893	6973	7053	7133	
8	6659	6739	6819	6899	6979	8	6456	6536	6616	6696	6776	8	7038	7118	7198	7278	7358	8	6835	6915	6995	7075	7155	
9	6681	6761	6841	6921	7001	9	6478	6558	6638	6718	6798	9	7060	7140	7220	7300	7380	9	6857	6937	7017	7097	7177	
10	6703	6783	6863	6943	7023	10	6500	6580	6660	6740	6820	10	7082	7162	7242	7322	7402	10	6879	6959	7039	7119	7199	
11	6725	6805	6885	6965	7045	11	...	6602	6682	6762	6842	11	7104	7184	7264	7344	7424	11	...	6981	7061	7141	7221	
12	...	6827	6907	6987	7067	12	6704	6784	6864	12	...	7206	7286	7366	7446	12	7083	7163	7243	
13	6929	7009	7089	13	6806	6886	13	7308	7388	7468	13	7185	7265	
14	7031	7111	14	6908	14	7410	7490	14	7287	
15	7133	15	15	
...
23	23	23	23	

^a Experimentally observed masses (bold type) that satisfy condition $0 \leq n \leq di + s + 1$ are enclosed by rectangles.

Table 3. Bikunin CS Chain Compositions Determined by FTICR-MS Analysis of the Mixture

	composition	number of possible sequences ^a	M_{odd}^b
I	GalNAc(GlcAGalNAc) ₁₁ (SO ₃) ₆ GlcAGalGalXylol	924	5505
II	GalNAc(GlcAGalNAc) ₁₂ (SO ₃) ₆ GlcAGalGalXylol	1716	5884
III	GalNAc(GlcAGalNAc) ₁₂ (SO ₃) ₇ GlcAGalGalXylol	1716	5964
IV	GalNAc(GlcAGalNAc) ₁₃ (SO ₃) ₆ GlcAGalGalXylol	3003	6263
V	GalNAc(GlcAGalNAc) ₁₃ (SO ₃) ₇ GlcAGalGalXylol	3432	6343
VI	GalNAc(GlcAGalNAc) ₁₄ (SO ₃) ₆ GlcAGalGalXylol	5005	6643
VII	GalNAc(GlcAGalNAc) ₁₄ (SO ₃) ₇ GlcAGalGalXylol	6435	6723
VIII	GalNAc(GlcAGalNAc) ₁₅ (SO ₃) ₆ GlcAGalGalXylol	8008	7022
IX	GalNAc(GlcAGalNAc) ₁₅ (SO ₃) ₇ GlcAGalGalXylol	11440	7102

^a Number of possible sequences was calculated as nCr , where n is the number of sulfation sites, and r is the number of sulfo groups ^b Monoisotopic mass of fully protonated GAG chain rounded off to the nearest unit

and OH absent from the residue formulas, and 203 mass units are added to the chains containing odd numbers of sugars to account for the NRE GalNAc residue.

$$M_{\text{odd}} = 379 \times di + 80 \times s + 22 \times n + (634 + 203 + 18) \quad (1)$$

$$M_{\text{even}} = 379 \times di + 80 \times s + 22 \times n + (634 + 18) \quad (2)$$

Expressions 1 and 2 make chemical sense only if condition 3 is satisfied: the number of sodium-cationized acidic groups does not exceed the total number of acidic groups in a chain, which includes GlcA and SO₃.

$$0 \leq n \leq di + s + 1 \quad (3)$$

From expressions 1 and 2, a master list containing all possible neutral masses in the 5–7 kDa range was generated and searched for matches to the experimental neutral masses satisfying condition 3. Table 2 illustrates the assignment of masses in groups VI, VII, VIII, and IX from Table 1. Masses in group VI were assigned to a 33-saccharide hexasulfated polysaccharide chain, but not to a 34-saccharide hexasulfated chain, because in the latter case, experimental masses 6797, 6775, and 6753 would imply negative values of n , which is impossible under the given experimental conditions. The assignment of experimental neutral masses resulted in a list of nine polysaccharide compositions summarized in Table 3. Simulated mass spectra generated for each of the nine compositions were in agreement with the experimental mass spectra (Figure 4). Interestingly, all assigned masses corresponded to GalNAc-terminated polysaccharides consisting of odd numbers of residues, and only two sulfation states were prominent, hexasulfated and heptasulfated.

ESI-MS and CID tandem MS characterization of the non-reducing end (NRE) and linkage region oligosaccharides allowed us to determine the positions of two sulfo groups. Bikunin GAG mixture was exhaustively digested with a combination of two endolyases, chondroitinase ABC and endolytic chondroitinase AC. The LC-MS profile of the resulting mixture indicated the presence of three oligosaccharides: Δ UAGalNAc (m/z 379), Δ UAGalNAc4S (m/z 458), and Δ UAGalGalXylol(S) (m/z 713),

(52) Yamagata, T.; Saito, H.; Habuchi, O.; Suzuki, S. *J. Biol. Chem.* **1968**, *243*, 1523–1535.

(53) Gal, J.-F.; Maria, P. C.; Raczynska, E. D. *J. Mass Spectrom.* **2001**, *36*, 699–716.

(54) Zaia, J. *Mass Spectrom. Rev.* **2004**, *23*, 161–227.

(55) de Waard, P.; Vliegenthart, J. F.; Harada, T.; Sugahara, K. *J. Biol. Chem.* **1992**, *267*, 6036–6043.




Figure 4. Experimental (a) and simulated (b) negative-ion FTICR mass spectra of the bikunin CS-A mixture showing $[M - 15H + 5Na]^{-10}$ ion which was assigned to GalNAc(GlcAGalNAc)₁₁(SO₃)₆GlcAGalGalXylol.




Figure 5. EDD mass spectrum of the NRE monosulfated trisaccharide obtained through the endolytic chondroitinase AC digestion of the bikunin CS.

and a terminal GalNAc residue (m/z 220). The ion corresponding to the monosulfated linkage region tetrasaccharide (m/z 713) was subjected to a tandem MS (MS^2) experiment and yielded a major fragment resulting from a glycosidic bond cleavage between Δ UA and GalGalXylol(S) (m/z 555). The MS^3 fragmentation of the ion at m/z 555 resulted in the cleavage of a glycosidic bond between two Gal residues and detection of a fragment GalXylol (m/z 241), which indicated that the sulfo group was located on the Gal residue linked to Δ UA (data not shown). Thus, the linkage region tetrasaccharide structure was determined as GlcAGal4SGalXylol, which is consistent with the structure of the bikunin linkage region hexasaccharide described by Sugahara and co-workers.²³

The GAG mixture was depolymerized with the exolytic chondroitinase AC⁵⁰ to determine the structure of the NRE. LC-MS analysis of the digestion mixture detected two products:




Figure 6. (A) PAGE analysis of bikunin CS. Direction of migration is from top to bottom. Lane 1, bikunin CS mixture; lanes 2–8, fractions of the mixture isolated by preparative PAGE followed by electroblotting. (B) FTICR-MS analysis of the fraction in lane 6: portion of the spectrum showing peaks corresponding to several components with multiple charge states. (C) Experimental and simulated FTICR mass spectra of the 603.13 m/z peak, corresponding to $[M - 11H]^{11-}$ ion of a hexasulfated, 33-monomer CS chain.

GalNAc and GalNAcGlcAGalNAc(S), m/z 220 and m/z 679, respectively. Fragmentation of the monosulfated trisaccharide (m/z 679) by EDD (Figure 5) unambiguously identified the sulfate position as C4 of midchain GalNAc residue. Considering the action pattern of exolytic chondroitinase AC and presence of GalNAc residue in the digestion mixture, it is reasonable to expect an unsulfated trisaccharide, β -D-GalNAc(1 \rightarrow 4)- β -D-

Table 4. Bikunin CS Chain Compositions Determined by FTICR-MS Analysis of the Isolated Fraction (Figure 6, Lane 6)

	composition	M_{obs}^a
VI-A	GalNAc(GlcAGalNAc) ₁₄ (SO ₃) ₄ GlcAGalGalXyloI	6483
VI-B	GalNAc(GlcAGalNAc) ₁₄ (SO ₃) ₅ GlcAGalGalXyloI	6563
VI	GalNAc(GlcAGalNAc) ₁₄ (SO ₃) ₆ GlcAGalGalXyloI	6643
VII	GalNAc(GlcAGalNAc) ₁₄ (SO ₃) ₇ GlcAGalGalXyloI	6723
VIII-A	GalNAc(GlcAGalNAc) ₁₅ (SO ₃) ₅ GlcAGalGalXyloI	6942
VIII	GalNAc(GlcAGalNAc) ₁₅ (SO ₃) ₆ GlcAGalGalXyloI	7022
IX	GalNAc(GlcAGalNAc) ₁₅ (SO ₃) ₇ GlcAGalGalXyloI	7102

^a Monoisotopic mass of fully protonated GAG chain rounded off to the nearest unit

GlcA(1 \rightarrow 3)- β -D-GalNAc(1 \rightarrow at the NRE of some bikunin GAG chains. Thus, two structures of the NRE are possible: β -D-GalNAc(1 \rightarrow 4)- β -D-GlcA(1 \rightarrow 3)- β -D-GalNAc(1 \rightarrow and β -D-GalNAc(1 \rightarrow 4)- β -D-GlcA(1 \rightarrow 3)- β -D-GalNAc4S(1 \rightarrow .

Isolation and Analysis of Size-Similar GAG Fractions.

According to FTICR-MS analysis, bikunin GAG mixture consists of long-chain linear polysaccharides (average molecular mass 6000 Da) with polydispersity arising from differences in sulfation (80 Da, 1% of average molecular mass) and/or chain length (379 Da, 6% of average molecular mass). The small differences in charge and size between the chains compared to their overall charge and size make the isolation of a single chain difficult. The separation of bikunin GAG mixture was carried out using preparative PAGE,⁴¹ which affords better resolution than any other method available for separation of polyanionic biomolecules. The nine major components in the mixture were immediately transferred onto a positively charged membrane by electroelution to avoid diffusion of GAGs through the gel. The membrane was washed and cut into strips each of which contained a size-uniform fraction of the bikunin GAG mixture. The GAGs eluted from the membrane with 2 M NaCl solution were desalted and analyzed by PAGE (Figure 6A) and FTICR-MS (Figure 6B). PAGE analysis indicated that each fraction contained 1–3 species, and a more efficient separation was achieved for the low-molecular-weight (low-MW) components of the mixture (Figure 6A).

FTICR-MS analysis of bikunin GAG fraction 5 (Figure 6A, lane 6) showed that even after extensive separation, a polydisperse mixture of GAG chains is still present. In addition to the previously identified hexasulfated and heptasulfated GAG chains (Table 3), sulfation states as low as four were detected (Figure 6B; Table 4). Similarly, the results of FTICR-MS analysis of a higher-molecular weight fraction, 6 (Figure 6A, lane 7) indicated that it contains GAGs consisting of 33, 35, 37, and 39 monosaccharides, each having 4–7 sulfo groups. Simulated mass spectra generated for validation of the peak assignment were in good agreement with the experimental mass spectra (Figure 6C).

The comparison of FTICR mass spectra obtained from size-fractionated bikunin GAGs and those from the mixture suggests that the mixture analysis is biased toward lower-MW chains, presumably owing to their higher ionization efficiency under the conditions used. In contrast, a separation step prior to the FTICR-MS affords mass spectra that more accurately represent the mixture composition.

Conclusion

The present work demonstrates for the first time a combined bottom-up and top-down approach in sequencing a GAG

component of a PG. The top-down approach relies on the high resolving power and sensitivity of FTICR-MS and complements the bottom-up approach which employs the time-tested enzymatic analysis in conjunction with LC using spectroscopic or mass spectrometric detection.

The analytical strategy presented here facilitates the molecular weight determination of intact CS chains derived from pooled human urinary bikunin. The bikunin-derived CS GAGs characterized by FTICR-MS are terminated with GalNAc residues and comprised 27–39 monosaccharides with 4–7 sulfo groups distributed along the polysaccharide chain. Enzymology in conjunction with LC-MS and tandem MS analyses allowed us to determine positions of two sulfo groups: in the linkage region tetrasaccharide, β -D-GlcA(1→3)- β -D-Gal4S(1→4)- β -D-Gal(1→4)-D-Xylol; and in the NRE trisaccharide, β -D-GalNAc(1→3)- β -D-GlcA(1→4)- β -D-GalNAc4S(1→). The results of FTICR-MS analysis of the bikunin GAGs separated by PAGE indicated that the median size of the bikunin CS used in this study is 33 monosaccharides (Figure 6, Table 4). The combined FTICR-MS and PAGE data suggest that the size of bikunin CS chains varies between 23 and 45 monosaccharides. Interesting structural features of the bikunin CS such as the odd number of monosaccharides, sulfation of NRE trisaccharide, and the presence of more than 5 sulfo groups were not described previously.

Beginning the study, we expected to find a tremendously complex GAG mixture. There could be 14 chain sizes and 34 compositions satisfying the ratios of unsulfated to sulfated disaccharides (1.8 and 3) and chain lengths of 12–18 disaccharides as reported in previous studies. On the basis of this information, more than 200,000 structures of bikunin CS GAGs

could be written. We established that more than 90% of bikunin CS chains in a large pooled sample fall within a relatively narrow size distribution, 27–35 monosaccharides, which reduced the number of possible structures 2-fold. Determining that each CS chain contains an odd number of monosaccharides and characterizing the structures of the non-reducing end trisaccharide and the linkage region tetrasaccharide further reduced the number of possible structures by an order of magnitude.

The chain length and sulfation of the urinary bikunin GAG are altered in inflammation and renal stone disease,^{26,27,34} serving as the disease markers. These characteristics can be assessed using FTICR-MS, which should facilitate diagnostic studies involving bikunin. The amount of bikunin PG used in the present study for the FTICR-MS molecular weight determination of the bikunin GAG did not exceed 100 μ g, a physiological amount, considering a 1–5 μ g/mL range concentration of bikunin in human urine^{15,36} and >100 μ g/mL in plasma.³⁰ Thus, the described strategy has a potential application in characterization of bikunin CS obtained from individual patients. Future work will be directed toward further structural analysis of the bikunin CS, particularly, the characteristics and distribution of sulfated domains.

Acknowledgment. This work was supported by NIH Grant GM38060.

Supporting Information Available: ¹H NMR of bikunin GAG and additional PAGE and FTICR-MS data. This material is available free of charge via the Internet at <http://pubs.acs.org/>.

JA0778500